HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Telemedicine in oncology: Virtual solution to a very real problem
• Is home-based remote monitoring ready for prime time in oncology?
• On killing innocents: Anzac Day revisited Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Hazardous drug exposures: Implications for the oncology APP Christopher R. Friese, PhD, RN, AOCN®, FAAN
• Telemedicine working group aims to address ‘big gaps’ of emergency cancer care
• Diet, supplements may affect immunotherapy response among patients with melanoma
• Liquid biopsy comparable to tissue biopsy in detecting biomarkers in NSCLC
• Savolitinib, osimertinib combination may benefit certain patients with EGFR-mutated lung cancer
• Standards evolve for adjuvant therapy of melanoma
• Immunotherapy-chemotherapy combination should be first-line treatment for many patients with NSCLC
• More immunotherapy regimens ‘desperately needed’ for salvage treatment of advanced NSCLC
• Niraparib extends time without symptoms for women with recurrent ovarian cancer
• Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain
• Dendritic cell-based immunotherapy regimen extends OS in recurrent ovarian cancer
• Pregnancy among young women with breast cancer requires tailored support, multidisciplinary approach
• Extent of sentinel lymph node biopsy influences lymphedema risk
• Pembrolizumab plus axitinib new standard first-line treatment for advanced kidney cancer
• Tivozanib shows PFS benefit over sorafenib for advanced kidney cancer
• Sacituzumab govitecan response rates 'promising' in metastatic urothelial cancer
• Pembrolizumab shows durable survival benefit in advanced non-small cell lung cancer
• Allogeneic transplant fails to confer survival benefit for pediatric leukemia subtype
• Direct oral anticoagulants do not increase incidence of intracranial hemorrhage
• Right to Try Act may undermine palliative care in pediatric oncology
• Daunorubicin linked to lower cardiomyopathy risk than doxorubicin in childhood cancer survivors
• Atezolizumab plus chemotherapy approved for triple-negative breast cancer, small cell lung cancer
• FDA advisory committee calls for more data on selinexor for relapsed multiple myeloma
• FDA approves Lonsurf for adults with metastatic gastric, gastroesophageal junction adenocarcinoma